Surgical Science Sweden AB (publ) (STO:SUS)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 1.68B |
| Revenue (ttm) | 992.34M |
| Net Income (ttm) | 66.82M |
| Shares Out | 51.03M |
| EPS (ttm) | 1.31 |
| PE Ratio | 25.14 |
| Forward PE | 14.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93,565 |
| Average Volume | 226,566 |
| Open | 33.40 |
| Previous Close | 33.40 |
| Day's Range | 32.42 - 33.62 |
| 52-Week Range | 23.70 - 162.80 |
| Beta | 0.58 |
| RSI | 50.02 |
| Earnings Date | May 20, 2026 |
About STO:SUS
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnosti... [Read more]
Financial Performance
In 2025, STO:SUS's revenue was 992.34 million, an increase of 12.25% compared to the previous year's 884.09 million. Earnings were 66.82 million, a decrease of -49.24%.
Financial StatementsNews
Surgical Science Sweden AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 15% local currency sales growth and record license revenues, though currency headwinds and a contract change with Intuitive will impact 2026. Operational efficiency improved, with cost savings realized and new products launched, supporting a positive long-term outlook.
Surgical Science Sweden AB Transcript: CMD 2025
A new strategy targets five business segments, aiming for 10%-15% annual revenue growth and at least 15% Adjusted EBIT by 2027. Profitability improvements, product innovation, and expanded sales channels are central, with a planned move to the Nasdaq Main Market to broaden investor access.
Surgical Science Sweden AB Earnings Call Transcript: Q3 2025
Q3 2025 delivered record sales and improved profitability initiatives, with strong growth in Europe and Industry OEM, but margin pressure from currency and product mix. Robotics and ultrasound segments show high demand, while U.K. and U.S. markets remain challenging.
Surgical Science Sweden AB Earnings Call Transcript: Q2 2025
Q2 sales declined 2% year-over-year to SEK 209 million, with negative currency effects and weaker U.S. and China markets, but backlog increased and Europe grew 22%. Gross margin fell to 65%, EBIT margin was -11%, and management remains confident in 2026 targets, driven by organic growth and ongoing strategic initiatives.
Surgical Science Sweden AB Earnings Call Transcript: Q1 2025
Q1 2025 delivered 33% sales growth and record license revenues, driven by strong performance in simulation and the integration of Intelligent Ultrasound, despite one-off costs and macroeconomic headwinds. Revised 2026 targets reflect market realities, with a positive long-term outlook for robotics and OEM.
Surgical Science Sweden AB Earnings Call Transcript: Q4 2024
Record Q4 sales and strong Industry OEM growth offset a weak start in Educational Products, with major strategic wins including a Southeast Asia contract and the Intelligent Ultrasound acquisition. The outlook is positive, especially for Industry OEM, but Educational Products face ongoing budgetary headwinds.
Surgical Science Sweden AB Transcript: M&A Announcement
The acquisition will double ultrasound simulation sales, expand global reach, and create a world-leading product portfolio. Cost and revenue synergies are expected, with integration and cross-selling opportunities beginning in 2025. Completion is targeted for Q1 2025.
Surgical Science Sweden AB Earnings Call Transcript: Q3 2024
Q3 2024 saw 12% currency-adjusted growth and a 20% EBIT margin, with both business segments expanding. Educational Products is set for strong growth in 2025, while Industry/OEM posted robust simulator and license sales. Cash position remains strong at SEK 666 million.
Surgical Science Sweden AB Earnings Call Transcript: Q2 2024
Q2 saw a strong rebound in Educational Products and continued growth in Industry OEM, with total sales of SEK 212 million and a 16% operating margin. Growth in 2024 hinges on large tenders, while license revenue from da Vinci 5 is expected in 2025.